Companies
- Companies
- Company details
BioAlliance Pharma SA
Out-licensing
Doxorubicin-loaded Transdrug Awarded Orphan Drug Status: Targeting Advanced Hepatocarcinoma and Liver Metastasis More
Elucidation of a New Class of HIV Integrase Inhibitors Synergistic with other Antiretroviral Agents: Phase I Clinical Trials of FZ 41 More
Identification of Novel Targets and Novel Drugs: AMEP and Zyxin as Potential Anti-Cancer Targets More
The Lauriad® Drug Delivery Technology in Clinical Trials for the Treatment of Oropharyngeal Candidiasis, Labial Herpes and Cancer Pain More
Related Reports
Market Research Reports provided by reports.iptechex.com
Nov 2010 - 60 pages - $500
Nov 2010 - 125 pages - $600
Feb 2011 - 32 pages - $125
May 2011 - 38 pages - $125
Jul 2010 - 75 pages - $750
Dec 2010 - 12 pages - $99
Nov 2010 - 15 pages - $99
Sep 2010 - 14 pages - $99
Mar 2011 - 82 pages - $250
Apr 2011 - 5 pages - $100
Contact details
Gilles Avenard
Head office
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us